GAN & LEE PHARMACEUTICALS. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.52 CNY | +0.06% |
|
+2.86% | -7.84% |
| Sales 2024 * | 3.65B 504M | Sales 2025 * | 4.6B 635M | Capitalization | 28.97B 4B |
|---|---|---|---|---|---|
| Net income 2024 * | 704M 97.22M | Net income 2025 * | 1.18B 163M | EV / Sales 2024 * | 7.31 x |
| Net cash position 2024 * | 2.27B 314M | Net cash position 2025 * | 3.07B 425M | EV / Sales 2025 * | 5.63 x |
| P/E ratio 2024 * |
41
x | P/E ratio 2025 * |
24.4
x | Employees | 4,482 |
| Yield 2024 * |
0.33% | Yield 2025 * |
0.41% | Free-Float | 49.4% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.06% | ||
| 1 week | +2.86% | ||
| Current month | -3.04% | ||
| 1 month | -3.04% | ||
| 3 months | +13.90% | ||
| 6 months | -8.97% | ||
| Current year | -7.84% |
1 week
45.50
49.28
1 month
45.5052.23
Current year
32.1052.77
1 year
32.1062.90
3 years
30.53134.97
5 years
30.53204.41
10 years
30.53204.41
| Managers | Title | Age | Since |
|---|---|---|---|
Kai Du
CEO | Chief Executive Officer | 47 | 07-12-31 |
Zhong Ru Gan
FOU | Founder | 76 | 98-06-16 |
Tao Zhang
CHM | Chairman | 46 | 04-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhong Ru Gan
FOU | Founder | 76 | 98-06-16 |
Kai Du
CEO | Chief Executive Officer | 47 | 07-12-31 |
Wei Qiang Song
BRD | Director/Board Member | 42 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 35 M€ | -5.85% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 48.52 | +0.06% | 7,736,420 |
| 24-05-30 | 48.49 | +2.52% | 13,271,780 |
| 24-05-29 | 47.3 | +1.05% | 5,160,470 |
| 24-05-28 | 46.81 | -1.14% | 5,936,692 |
| 24-05-27 | 47.35 | +1.94% | 9,110,995 |
End-of-day quote Shanghai S.E., May 30, 2024
More quotes
Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
48.52
CNY
Average target price
63
CNY
Spread / Average Target
+29.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.84% | 4B | |
| -2.29% | 89.38B | |
| -3.95% | 37.92B | |
| -13.07% | 32.04B | |
| +63.05% | 26.03B | |
| -22.14% | 14.14B | |
| -7.96% | 12.88B | |
| -9.33% | 11.77B | |
| -46.33% | 10.85B | |
| +5.77% | 8.92B |
- Stock Market
- Equities
- 603087 Stock
